Forecast of $0.24 EPS for Imperva, Inc. According to Zacks Investment Research

Forecast of $0.24 EPS for Imperva Inc.

Zacks reports that Wall Street brokerages forecast an $0.24 EPS for Imperva Inc. (NYSE:$IMPV). The estimates range from $0.26 to $0.23. During the same quarter last year, Imperva reported a $0.08, which would indicate a 200% growth rate. Earnings results are predicted to arrive Thursday, November 2nd.

Zacks also reported that analysts forecast full year earnings of $0.81 for the current year. Exact estimates ranged from $0.79 to $0.83. EPS estimates range from $0.73 to $1.04 for an average annualized EPS forecast of $0.94 per share.

On Tuesday, trading of Imperva opened at $43.20. Their market cap currently is currently at $1.46 billion. They have a 50 day moving average of $44.11 and a 200 day moving average of $45.69. Their current 52 week high is $57.24 and their 52 week low is $34.40.

The last earnings result report was issued by Imperva on Thursday, July 27th. They beat the consensus estimate of -$0.15 with a reported -$0.10 EPS. During the same quarter the previous year, the company reported -$0.23. They reported revenue of $74.44 million, just beating the consensus estimates of $74.30 million. On a year-over-year basis, total revenue was up 28.6%. They also reported a negative Net Margin of -4.69% and a negative Return on Equity of -5.00%.

Multiple analyst firms also recently weighed in on the stock;

  • Susquehanna Bancshares Inc: On Wednesday, June 7th, the firm commenced coverage of the stock with a ‘Positive’ rating and a price target of $60.00.
  • Stephens: On Thursday, July 13th, Stephens restated an ‘Overweight’ rating and increased their target price from $53.00 to $61.00.
  • Evercore ISI: In a report on Friday, July 28th, Evercore gave the company a ‘Buy’ rating and a price target of $56.00.
  • Monness Crespi & Hardt: Also on Friday, July 28th, this firm gave the company a ‘Buy’ rating and upped their price target from $55.00 to $57.00.
  • ValuEngine: Finally, on Tuesday, July 11th, ValuEngine dropped shares of Imperva from ‘Hold’ to ‘Sell’.

In insider news, Director Anthony J. Bettencourt sold 99,598 shares for an average price of $43.59 with a total value of $4,341,476.82. The transaction took place on Thursday, August 24th. He currently owns 99,598 shares valued at $4,341,476.82. All together, insiders currently own 2.20% company’s stock.

Multiple institutions recently altered their holdings in the company;

  • ETF Managers Group LLC bought a new stake in the company during the 2nd quarter with an initial investment of $41,888,000.
  • Clearbridge Investments LLC bought an additional 403,809 shares in the 1st quarter, an increase of 47.0%, giving them a total of 1,262,507 shares valued at $51,826,000.
  • Eagle Asset Management Inc bought an additional 192,625 shares during the 2nd quarter, for a total of 1,279,848 shares valued at $61,240,000.
  • BlackRock Inc bought an additional 215,170 shares during their 2nd quarter, an increase of 11.3%, for a total of 2,124,043 shares valued at $101,635,000.
  • Vanguard Groups Inc. bought an additional 99,799 shares in the 2nd quarter, an increase of 4.3%, for a total of 2,439,240 shares valued at $116,718,000.

Institutional ownership currently accounts for 92.72% of the total active shares.

Featured Image: Depositphotos/© SergeyNivens

If You Liked This Article Click To Share